Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MWX203 S6
- Development stage
- Unknown
- Lead developer
- Shanghai Minwei Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
MWX203 S6 (also referred to as MWX203 or MWX-203) is an investigational small interfering RNA (siRNA) therapeutic developed by Shanghai Minwei Biotechnology, a subsidiary of Lepu Medical Technology. It is designed to target angiopoietin-like 3 (ANGPTL3) to treat lipid disorders, including hyperlipidemia, dyslipidemia, and complex dyslipidemia. By utilizing RNA interference (RNAi) to silence ANGPTL3 expression, MWX203 aims to lower serum triglycerides and cholesterol levels. The drug is administered subcutaneously and is currently in Phase 2 clinical development in China, both as a monotherapy and in combination with other lipid-lowering therapies like inclisiran.
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on MWX203 S6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MWX203 S6.